COUNTRY ANALYSIS REPORT: MEXICO VS U.S.A HEALTHCARE MERCK - DIABETES Group 14 – Campus Santa Fe: Angelica Hidalgo 1461526 Alejandro Meza 1464801 Cinthia Merlos 1462113 Juan José Ibarra 1465263 April 10th, 2012 INDEX 1. INTRODUCTION 2. ECONOMIC VARIABLES
Words: 4412 - Pages: 18
High-Technology Acquisitions Final Project -Acquisition Proposal: To Acquire: May 2012 Table of Content Executive Summary I A. Purpose I B. Background I C. The Rational for the Acquisition I D. Standalone, Synergy and Premium Valuations II E. Integration Plan II Part 1 - The Rational of the Acquisition 1 1. Pfizer's Strategy 1 1.1. Pfizer Growth Strategy 2 2. Pfizer's Road Map 4 2.1. Pfizer's Acquisitions Rational 4 3. The strategy behind the acquisition
Words: 10031 - Pages: 41
Claris Lifesciences Claris Lifescienceswas originally founded as Oracle Laboratories Limited on July 19, 1994, as a public limited company. They received the certificate for commencement of business on July 28, 1994. Subsequently, the company name was changed to Core Laboratories Limited as they were acting as the marketing and distribution agent for Core Healthcare Limited at the time. They changed the name of the Company again to Claris Lifesciences Limited on March 31, 1999. Since then, Claris
Words: 835 - Pages: 4
dollars in revenues on prescription drugs that have patent protection. Once a drug loses its patent protection, other manufacturers are allowed to make a generic form of the drug. Having a generic form of a brand name drug available should increase the supply in the market for consumers by driving cost down. This paper will discuss the effect of generic drugs and evaluate their effect on the supply and demand for drugs that no longer have patent protection. An example of a prescription drug that recently
Words: 1447 - Pages: 6
its R&D investment and make a fair profit during the period of exclusivity. Second, it is limited geographically, as some countries will not respect intellectual property and allow their own pharmaceutical companies to copy innovations, making generic drugs even before the original patent expires. Third, it lacks the most important element of a monopoly: price control. In most countries, the prices of drugs are set by a governmental agency. The manufacturers are merely consulted; their influence
Words: 261 - Pages: 2
which means that there won’t be a cheaper substitute. This is where the “Power of Suppliers” comes in. Pharmaceutical companies can charge a premium price for their patented drugs without having to fear other companies coming in and offering a generic version of the same drug for cheaper. 80% of R&D is focused at generating new products, and only 20% is spent trying to improve already existing products. This is the case because the power and money generating for these pharmaceutical companies
Words: 308 - Pages: 2
Despite having a prescription for a specific brand medication, we are often served a generic drug and, often but not always, told that it is “the same” but less expensive. Is it really? Some generics of old medications such as the benzodiazepines and the tricyclics are really inexpensive, with most of the bill going toward pharmacy costs. As an example, the price of a low dose of amitriptyline for the management of chronic pain for 1 month is probably not much more than that of a cappuccino in a
Words: 1180 - Pages: 5
The Upjohn Company: The Upjohn - Pharmacia Merger 3 Business Analysis and Valuation Applications harmacia & Upjohn will be a powerful new competitor in the global pharmaceutical industry. For both Pharmacia and Upjohn, this merger is a bold strategic move to build a highly competitive company as the worldwide pharmaceutical industry continues to consolidate. The new company will be positioned to attain its goals of revenue growth above the industry average and operating margins exceeding 25%
Words: 13956 - Pages: 56
INDIAN PHARMACEUTICAL INDUSTRY – AN OVERVIEW 1. Overview The Indian Pharma industry is one of the fastest growing sectors with approximately 20,000 manufacturing units. The industry that is highly price sensitive ranks thirteenth in the global pharmaceutical market in value terms and fourth in volume terms. The country has tremendous export potential in the areas like custom synthesis, R&D, clinical trials, and Bioinformatics. The industry produces 60,000 finished medicines and roughly 400
Words: 1530 - Pages: 7
than let the patent infringement case go to trial because Apotex voiced that they it expected immediate approval by the FDA. Bristol-Myers also knew that the FTC had opposed the arrangement between Bristol-Myers Squibb and Apotex that restricted the generic drugs from being placed on the market. “Under the consent decree the FTC and the state attorneys general had to approve any Bristol-Myers Squibb arrangements that could be
Words: 932 - Pages: 4
